CSF1R and central nervous system cancer: Coniglio et al. further demonstrated that introduction of PLX3397, a CSF-1R inhibitor, was capable of decreasing the recruitment of GL261-associated microglia/macrophages as well as glioma invasiveness in vivo (Figure 5 and Table 1) [118].